Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Celgene Buying Gloucester Pharma for $640 million

By Pharmaceutical Processing | December 7, 2009

NEW YORK (AP) — Celgene Corp. announced today it will buy privately held Gloucester Pharmaceuticals Inc. for $640 million, getting access to key cancer drugs. The deal includes $340 million in cash upfront and $300 million in future regulatory milestone payments. Gloucester, headquartered in Cambridge, Mass., develops drugs for blood cancers with limited treatment options. The FDA approved Gloucester’s drug Istodax in November as a treatment for cutaneous T-cell lymphoma. It is approved only for patients who were on at least one previous therapy. Gloucester is seeking other approvals, and European regulators are reviewing Istodax. The company is testing drugs for cutaneous T-cell lymphoma and peripheral T-cell lymphoma, which are both types of non-Hodgkin’s lymphoma. It is also developing combinations of drugs for solid tumors and for multiple myeloma. Celgene’s drugs include Revlimid, which is used against multiple myeloma, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia; and Vidaza, which is approved for treatment of the bone marrow disease myelodysplastic syndrome and acute myeloid leukemia. Celgene, based in Summit, N.J., said the purchase will close in the first quarter. It will add to profit in 2011 but have no impact in 2010, Celgene said.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE